logo
Share SHARE
FONT-SIZE Plus   Neg

Lupin Launches Generic Tricor Tablets In US

Pharma major Lupin Ltd., said its subsidiary Lupin Pharmaceuticals Inc. had launched its Fenofibrate tablets in 48 mg and 145 mg strengths in the US, for which it had received final approval from the US FDA.

Lupin's Fenofibrate tablets are the AB rated generic equivalent of Abbott's Tricor tablets and are indicated for primary hypercholesterolemia or mixed dyslipidemia and severe hypertriglyceridemia.

Abbott's Tricor tables, 48 mg and 145 mg, had sales of $1.26 billion as per IMS Health, June 2012.

Commenting on the approval, Lupin Pharmaceuticals CEO and Group President Vinita Gupta said, "We are very happy to bring this product to market in the US. Patients can be assured that they are receiving the same high quality product they have been accustomed to a a more affordable price."

At the BSE, Lupin shares are currently trading at Rs.565.50, up 0.60 percent from the previous close.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Shares of Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) were gaining around 4 percent in the trading in South Korea after the company reported significant growth in its first-quarter profit with higher sales mainly in memory and display businesses. For the full year, the company expects overall earnings to grow from last year. Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) reported that its net profit for the first-quarter of 2017 rose 46% to 7.68 trillion South Korean won or $6.8 billion from 5.25 trillion won for the same period a year earlier. The company said that it would not adopt a holding company structure. Casino operator Las Vegas Sands Corp. (LVS), Wednesday reported an increase in profit for the first quarter, gambling business in Macao, China, the world's biggest gambling market, revives. Earnings for the quarter trumped Wall Street expectations, as did revenues. First-quarter profit rose to $480...
comments powered by Disqus
Follow RTT